BioNTech AG is Europe’s largest privately held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases.
The Company combines all building blocks of individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing.
Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen receptors and T-cell receptor-based products to novel checkpoint immunomodulators.
BioNTech was founded in 2008 & is based in Mainz, Rheinland-Pfalz, Germany.
BioNTech has raised a total of $270M in 1 funding rounds. The company received their last funding on Jan 4, 2018 where they cashed $270M from Redmile Group & 5 other investors in Series A funding round.